Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib … Continue reading "Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy"
DID YOU KNOW?
Glycerin is among the most popular ingredients in beauty products, behind water and fragrance.1 With a 50+ year history of use, glycerin is a deceptively simple molecule classified as a powerful humectant that is anything but basic.
Glycerin is recognized by the U.S. Food & Drug Administration (FDA) as an over-the-counter skin protectant when used between 20-45%.2
… 
"The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas" announces expansion of its educational reach with a digital online free image gallery. The inclusive dermatology atlas online image gallery provides more than 800 images of 110 commonly diagnosed dermatologic conditions in an array of skin tones, including skin of color, and compliments the print atlas which was first released … 
What mutation is responsible for this clinical presentation in a patient with both thyroid dysfunction and chronic candidal infections?
A. Autoimmune regulator (AIRE)
B. Phosphatase and tensin homolog (PTEN)
C. Tyrosine related protein 1 (TRP1)
D. Fumarate hydratase (FH)
E. Lysosomal trafficking regulator (LYST)
To find out the correct answer and read the explanation, … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Vishal A. Patel (fellowship trained Mohs micrographic surgeon who serves as Director of Cutaneous Oncology at the GW Cancer Center and Director of Dermatologic Surgery at the GW Department of Dermatology) about routine skin cancer checks. Watch as he provides insight on this complex questio …